Find an expert

I am a medicinal chemist and postdoctoral research fellow at the University of Queensland, Australia, where I obtained my BSc (Hons) with a major in organic chemistry in 2011. Following this, I worked at the Institute for Future Environments and later the Centre for Tropical Crops and Biocommodities at QUT, where I gained experience in analytical chemistry, as well as molecular biology and genetics. In 2015, I returned to UQ to begin my PhD in the design and synthesis of novel antifungals targeting invasive infection under the supervision of Prof. Craig Williams and Prof. Luke Guddat, which I completed in 2019. My combined experience in synthetic chemistry - particularly in the synthesis of heterocyclic small molecules - and molecular biology has since led to my current position at UQ under the supervision of Prof. Avril Robertson, where my focus is once again on the design and synthesis of novel antifungals. Broadly, my research interests lie in the pursuit of drug design and development campaigns addressing difficult or under-researched clinical concerns, and in particular, the use of novel bioisosteric approaches to improve drugability and drug efficacy.

More recently, I have developed an interest in Australian mushroom species. Very little recorded knowledge on our endemic mushrooms species exists. My research in this space seeks to characterise the genetic and molecular features of Australian wood rot mushrooms, which are critical players in maintaining and restoring the health of our unique forests ecosystems. With this information we aim to better understand our fungal biodiversity and the ecological roles they play, and to explore their potential uses in several industries. We are also investigating the biological activity of extracts and molecules derived from these mushrooms against models of human diseases, such as Alzheimer's, cancer, and drug-resistant microbial infections.

Associate Professor Annika Antonsson is a virologist with epidemiological training. Viruses can cause cancer, and Annika’s research has been focused on human papillomavirus (HPV) and its role in different types of cancer. HPV is the virus that causes cervical cancer.

Her current main research areas are oral HPV infections in the general population and HPV in mouth and throat cancer (mucosal squamous cell carcinomas of the head and neck; HNSCC).

Some cancers of the mouth and throat are increasing and some of this increase is caused by HPV infection. HPV is a sexually transmitted infection and changing sexual behaviour is believed to have caused the increase in HPV-positive tumours of the mouth and throat. Annika is investigating how often HPV in found in HNSCCs and if there are any lifestyle factors linked with having HPV or not to have HPV in tumours.

It is not known how common the potentially cancer-causing viruses are in the mouth of the general population, and this is another area of research Annika is looking into. She has also worked on HPV in skin (normal skin and cancer), infections in breast carcinogenesis, HPV in oesophageal cancer and polyomaviruses in normal skin and skin cancer.

Prof David Ascher is currently an NHMRC Investigator and Director of the Biotechnology Program at the University of Queensland. He is also Head of Computational Biology and Clinical Informatics at the Baker Institute.

David’s research focus is in modelling biological data to gain insight into fundamental biological processes. One of his primary research interests has been developing tools to unravel the link between genotype and phenotype, using computational and experimental approaches to understand the effects of mutations on protein structure and function. His group has developed a platform of over 40 widely used programs for assessing the molecular consequences of coding variants (>7 million hits/year).

Working with clinical collaborators in Australia, Brazil and UK, these methods have been translated into the clinic to guide the diagnosis, management and treatment of a number of hereditary diseases, rare cancers and drug resistant infections.

David has a B.Biotech from the University of Adelaide, majoring in Biochemistry, Biotechnology and Pharmacology and Toxicology; and a B.Sci(Hon) from the University of Queensland, majoring in Biochemistry, where he worked with Luke Guddat and Ron Duggleby on the structural and functional characterization of enzymes in the branched-chain amino acid biosynthetic pathway. David then went to St Vincent’s Institute of Medical Research to undertake a PhD at the University of Melbourne in Biochemistry. There he worked under the supervision of Michael Parker using computational, biochemical and structural tools to develop small molecules drugs to improve memory.

In 2013 David went to the University of Cambridge to work with Sir Tom Blundell on using fragment based drug development techniques to target protein-protein interactions; and subsequently on the structural characterisation of proteins involved in non-homologous DNA repair. He returned to Cambridge in 2014 to establish a research platform to characterise the molecular effects of mutations on protein structure and function- using this information to gain insight into the link between genetic changes and phenotypes. He was subsequently recruited as a lab head in the Department of Biochemistry and Molecular Biology at the University of Melbourne in 2016, before joining the Baker Institute in 2019 and the University of Queensland in 2021.

He is an Associate Editor of PBMB and Fronteirs in Bioinformatics, and holds honorary positions at Bio21 Institute, Cambridge University, FIOCRUZ, and the Tuscany University Network.

Dr Andy Barnes obtained his BSc (Hons) in Microbiology from Heriot-Watt University, Edinburgh and his PhD from the Medical School, University of Edinburgh. Andy worked for the Scottish Office Agriculture and Fisheries Department and at the Moredun Research Institute, Edinburgh before joining a small Canadian biotech company, Aqua Health Ltd, specialising in vaccines for aquaculture in 1993. In 1999, Aqua Health was bought by Swiss pharmaceutical giant Novartis and Andy worked in their animal health division for 4 years before beginning an academic career at The University of Queensland. Currently in the School of Biological Sciences, Andy’s Aquatic Animal Health Lab researches vaccines for the aquaculture industry and investigates health and immunity in aquatic animals ranging from reef-building corals, through prawns and oysters, to barramundi, stingrays and grouper.

Scott Beatson is an Associate Professor and NHMRC Career Development Fellow at The University of Queensland (UQ). He specializes in bacterial pathogenomics: using whole-genome sequencing to investigate transmission, pathogenesis and antibiotic resistance in bacteria. Recent work from his group includes genomic analyses of pandrug resistant enterobacteriaceae and the multidrug resistant Escherichia coli ST131 pandemic clone. He was awarded a PhD from UQ for his work in bacterial pathogenesis in 2002 and developed his career in bacterial genomics in the United Kingdom with the support of fellowships from the Royal Commission for the Exhibition of 1851 (University of Oxford) and the UK Medical Research Council (University of Birmingham). Since returning to Australia he has held fellowships from both the NHMRC and ARC and has led a successful research group in the School of Chemistry and Molecular Biosciences at UQ since 2008. He is also a member of the Australian Infectious Diseases Research Centre and the Australian Centre for Ecogenomics. In 2016 he received the Frank Fenner Award from the Australian Society for Microbiology in recognition of his contribution to microbiology research in Australia.

Gabrielle Belz originally trained in veterinary medicine and surgery and received her PhD in understanding the organisation of lymphatics and lymphoid tissues at The University of Queensland. After a short stint in Canada to work on B cells, she moved to St Jude Children’s Research Hospital to work with Peter Doherty supported by an NHMRC CJ Martin Fellowship. Here she established a number of systems that now allow tracking of virus-specific T cells and established the paradigm changing notion that CD4 T cell help was required for generating antiviral responses. She returned to The Walter and Eliza Hall Institute of Medical Research and uncovered the identity of the key dendritic cells necessary for initiating antiviral infections. Subsequently she was awarded the Burnet Prize and NHMRC Elizabeth Blackburn Fellowship. Her research contributions have been recognized by a number of awards including a Wellcome Trust Overseas Fellowship, HHMI international fellowship, ARC Future fellowship, Doctor of Veterinary Science and the Gottschalk Medal (Australian Academy of Science). Her laboratory focuses on deciphering the key cellular and transcriptional signals of protective immunity particularly by T cells and in understanding how innate immune cells develop and make novel contributions to mucosal immune defence.

Dr. Bialasiewicz worked at the Royal Children's Hospital and the Children's Health Queensland HHS for over 18 years conducting translational research and clinical support centering on infectious disease (primarily viral and bacterial) molecular diagnostics, general microbiology and molecular epidemiology. In 2019, he became a group leader at The University of Queensland's Australian Centre for Ecogenomics, expanding on a growing interest in the microbial ecology of the human body, it's role in health and disease, and ways to manipulated to achieve desirable outcomes. One Health microbial ecology, where human health is interconnected with the health of animals (both livestock and wildlife), and the broader environment is also an area of active interest. His background in virology has influenced the work he does, meaning a key focus of his microbial ecology works centres around the interactions between all types of microorgansims (bacteria, archaea, viruses, fungi, and micro-eukaryotes).

Ongoing work includes:

- Leveraging of emerging technologies to explore the hidden microbial diversity and their interactions in the human body.

- Using the technology to develop microbial (e.g. phage)-based treatments or preventatives to complex diseases (e.g. Otitis Media, Chronic Rhinosinusitis, GvHD).

- Understanding the genetics of antibiotic resistance spread.

A/Prof Lucy Burr is an experienced respiratory physician, training supervisor and clinical trials researcher at Mater Health and Mater Research – University of Queensland (UQ). She has a PhD (2017) in bronchiectasis microbiology and is an Associate Professor at the School of Medicine, UQ. She is the Director of Respiratory, Sleep and Cystic Fibrosis medicine at the Mater Hospital, Brisbane.

As well as directing the respiratory clinical service at the Mater, Lucy has an active role in teaching both specialist trainees and medical students. She is a RACP college supervisor and trains one advanced trainee and four basic trainees per year. She directly supervises four medical students in her clinical team per year. Lucy is also currently supervising 5 PhD students, researching diverse fields such as glucose control in cystic fibrosis, asthma, fatigue, IL-22 and the effect of sleep on social cognition.

Lucy is recognised nationally for her clinical work on respiratory infections. She is the chair of the Acute and Critical Care panel for the National COVID-19 clinical evidence taskforce and a member of the guideline leadership group. Additionally, she is the recent chair (2020-2022) of the expert reference group on COVID-19 for the Royal Australasian College of Physicians. She is a recent (2019- 2021) convenor of the respiratory infectious disease special interest group of the Thoracic Society of Australia and New Zealand, the Queensland TSANZ branch president and past president (2017-2020), a recent board director of the TSANZ national body and current Chair of the Australian Bronchiectasis Consortium. Lucy is currently serving on the TSANZ annual scientific meeting and World Bronchiectasis conference steering committees. She is recognised internationally for her work on Cystic Fibrosis (top 1.8% expertscape February 2024) and Bronchiectasis (top 2.2% expertscape February 2024) and has published in high impact clinical journals including the New England Journal of Medicine and the Lancet Respiratory Medicine, across a range of respiratory and infectious disease subjects, with >1500 citations in the past 5 years.

In addition to her clinical work, Lucy is the custodian and manager of the David Serisier Research biobank at Mater Research, a clinical repository of human samples from patients living with respiratory diseases. Lucy is also an experienced principal investigator on many pharmaceutical studies ranging from phase 1b to phase 4 studies investigating therapeutics for CF, IPF, COPD, COVID, influenza pulmonary hypertension and bronchiectasis. She has designed and lead non-pharmaceutical interventional studies investigating the role of macrolide in modulating inflammation in healthy adults. She is the group leader of the respiratory clinical trials unit at Mater Research, and the program lead for the chronic and integrated care program at Mater Research.

Lucy has a proven track record in collaborative and translational research. She is currently a consultant on 2 peer reviewed external grants totalling $1,306,000, including one involving biobanked samples, and is a chief investigator on a 2021 Ideas grant and a 2021 MRFF grant totalling more than $3 million dollars.

Dr Chan has a PhD in Genomics and Computational Biology from UQ. He underwent postdoctoral training at Rutgers University (USA) in algal genomics and evolution. He returmed to UQ in late 2011 as one of the inaugural Great Barrier Reef Foundation Bioinformatics Fellows.

Dr Chan joined the School of Chemistry and Molecular Biosciences in 2020 as a group leader at the Australian Centre for Ecogenomics (ACE). His group uses advanced computational approaches to study genome evolution and develop scalable approaches for comparative genomics.

Evolutionary and ecological genomics of marine invertebrate animals.

Animals evolve because their genomes need to respond to the constantly changing environment presented by both their external habitat and their internal microbial symbionts. Over evolutionary time, these different factors interact during development, when the animal body plan is being established, to generate the extraordinary animal diversity that graces our planet. In ecological time, early life history stages must detect and respond to the precise nature of their environment to generate a locally-adapted functional phenotype. Using coral reef invertebrates from phyla that span the animal kingdom, we study these gene-environment interactions using genomic, molecular and cellular approaches combined with behavioural ecology in natural populations. We work mostly with embryonic and larval life history stages of indirect developers, as these are crucial to the survival, connectivity, and evolution of marine populations. When not immersed in the molecular or computer lab, we are lucky enough to be immersed in the ocean, often in beautiful places!

Paul Dennis leads an exciting research group that applies cutting-edge technologies to understand the roles of microorganisms and their responses to environmental change.

He is also a passionate educator and public speaker who advocates for the importance of biological diversity and evidence-based environmental awareness. He has talked about his research on ABC Radio and a range of other media outlets.

His teaching covers aspects of ecology, microbiology, plant and soil science, and climatology. He considers these topics to be of fundamental importance for the development of more sustainable societies and takes pride in helping others to obtain the knowledge and skills they need to build a better future.

Paul's research has taken him to Antarctica, the Amazon Rainforest, high mountains and oceans. The approaches used in his lab draw on a wide range of expertise in molecular biology, ecology, statistics, computer science, advanced imaging and soil science. He applies these skills to a wide-range of topics and systems including plant-microbe interactions, Antarctic marine and terrestrial ecology, biogeography, pollution and human health.

Plant viruses and horticultural crop improvement

Dr Dietzgen is internationally recognised for his work on plant virus characterisation, detection and engineered resistance. Before joining UQ, Dr Dietzgen was a Science Leader in Agri-Science in the Queensland Department of Employment, Economic Development and Innovation. He previously held research positions at the University of Adelaide, University of California, Cornell University and University of Kentucky. Dr Dietzgen’s research interests are in molecular virus-plant-insect interactions, virus biodiversity and evolution, and disease resistance mechanisms. His focus is on the biology of RNA viruses in the family Rhabdoviridae and the molecular protein interactions of plant-adapted rhabdoviruses and tospoviruses. He has published extensively on plant virus characterisation and genetic variability, RNAi- mediated virus resistance and diagnostic technologies with 20 review articles and book chapters and over 65 peer-reviewed publications.

Birgitta Ebert’s research focuses on developing biotechnology concepts to address critical challenges such as pollution, climate change and overexploitation of natural resources.

She specializes in improving microbial catalysts for eco-friendly chemical and material production by leveraging metabolic engineering, synthetic biology, systems analysis, and modelling. Her goal is to create microbial cell factories that convert renewable resources and waste into valuable products, reducing reliance on petrochemicals. She collaborates closely with chemists and chemical engineers to enhance the integration of chemical and biological processes for improved efficiency and sustainability.

Birgitta has a background in Chemical Engineering and a PhD in Systems Biotechnology from TU Dortmund University (Germany). She led a research group in Systems Metabolic Engineering at the Institute of Applied Microbiology at RWTH Aachen University (Germany) from 2012 to 2019. In 2016, she expanded her expertise in Synthetic Biology by joining the Keasling lab at the University of California in Berkeley and the Joint BioEnergy Institute in Emeryville (USA).

Since April 2019, she has been at the Australian Institute for Bioengineering and Nanotechnology at the University of Queensland, applying her expertise to engineer microbial cell factories for fermentation-based manufacturing.

I am an entomologist with a research interest focused on studying host-pathogen interactions and discovering insect-specific viruses. I have investigated gene expression and the role of small non-coding RNAs in various host-pathogen models, particularly in crucial agricultural pests and medically significant vectors like the Aedes aegypti, responsible for transmitting dengue and Zika viruses. My previous project, aimed at exploring the function of Oryctes rhinoceros nudivirus in the biological control of the coconut rhinoceros beetle in the Pacific Islands, has substantially enhanced our comprehension of this invasive pest within the framework of an offshore biosecurity strategy. By establishing industry partnerships and securing funding to improve the Australian sugar industry, one of Australia's largest agricultural sectors, I have been able to focus on entomopathogenic viruses that affect root-feeding pests in sugarcane.

General Research specialises in: Evolutionary microbiology, Marine microbiology; Molecular phylogenetics, genomics and bioinformatics of bacteria; Planctomycete bacteria; Bacterial cell biology and structure.

Current research projects include: